Taltz Special Precautions

Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Infections: Treatment with Ixekizumab (Taltz) is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections (see Adverse Reactions).
Ixekizumab (Taltz) should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, patients should be carefully monitored and Ixekizumab (Taltz) discontinued if the patient is not responding to standard therapy or if the infection becomes serious. Ixekizumab (Taltz) should not be resumed until the infection resolves.
Ixekizumab (Taltz) must not be given to patients with active tuberculosis (TB). Anti-TB therapy prior to initiation of Ixekizumab (Taltz) in patients with latent TB should be considered.
Hypersensitivity: Serious hypersensitivity reactions, including some cases of anaphylaxis, angioedema, urticaria and, rarely, late (10-14 days following injection) serious hypersensitivity reactions including widespread urticaria, dyspnea and high antibody titers have been reported. If a serious hypersensitivity reaction occurs, administration of Ixekizumab (Taltz) should be discontinued immediately and appropriate therapy initiated.
Inflammatory bowel disease (including Crohn's disease and ulcerative colitis): Cases of new or exacerbations of inflammatory bowel disease have been reported with ixekizumab (see Adverse Reactions). Ixekizumab is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, ixekizumab should be discontinued and appropriate medical management should be initiated.
Immunizations: Ixekizumab (Taltz) should not be used with live vaccines. No data are available on the response to live vaccines; there are insufficient data on response to inactive vaccines (see Pharmacology: Pharmacodynamics under Actions).
Excipients: This medicinal product contains less than 1 mmol sodium (23 mg) per 80 mg dose, that is to say essentially "sodium-free".
Effects on ability to drive and use machines: Ixekizumab (Taltz) has no or negligible influence on the ability to drive and use machines.